Non-Alcoholic Fatty Liver Disease and the Left Ventricle Mass Index in Obese Children

Beray Selver1, Enver Simsek*, Ugur Kocabas and Yildiz Dallar

1Department of Pediatrics, Ankara Research and Training Hospital, Ankara, Turkey
2Department of Pediatrics, Division of Endocrinology, Eskisehir Osmangazi University, School of Medicine, Eskisehir, Turkey
3Department of Cardiology, Ankara Research and Training Hospital, Ankara, Turkey

Abstract

Objective: To investigate Nonalcoholic Fatty Liver Disease (NAFLD), the Left Ventricle Mass Index (LVMI), and the relationship between NAFLD and LVMI in obese children.

Material and methods: Systolic (SBP) and Diastolic (DBP) Blood Pressure and waist and hip circumferences were measured. Fasting blood glucose and insulin concentrations, total cholesterol, and Triglycerides (TG) were assayed. The diagnosis of NAFLD was based on sonographic evidence of a fatty liver. The Left Ventricle Mass (LVM) was calculated from two-dimensionally guided M-mode echocardiographic measurements of the left ventricle. LVMI was calculated as LVM (g/height (m)^2) and Left Ventricular Hypertrophy (LVH) was defined as LVMI ≥ 95th percentile for age and gender

Results: Forty-three obese children with NAFLD, 55 obese children without NAFLD, and 48 non-obese controls were studied. Fasting insulin, homeostasis model assessment-estimated insulin resistance (HOMA-IR) index, TG, and total cholesterol levels in the obese children were significantly higher than in the controls (all p < 0.001); SBP and DBP in the obese children were also higher than in the controls. LVMI was higher in the obese children (p < 0.001), although the mean LVMI did not differ significantly between obese children with and without NAFLD (p > 0.05). The prevalence of LVH differed significantly between the obese groups and controls (all p < 0.001), while there was no significant difference between the obese subjects with and without NAFLD. LVH was present in 5 of 48 (10.4%) control subjects, 25 of 79 (31.6%) obese subjects with normotensive subjects, and 6 of 19 (36.8%) obese subjects with hypertension. The prevalence of LVH differed significantly between the obese groups and controls (all p < 0.001), whereas no significant difference was observed between obese subjects with or without hypertension (p > 0.05). In a multiple linear regression analysis, NAFLD, SBP, and DBP were not correlated with LVMI. The LVMI was closely related to the Body Mass Index-Standard Deviation Score (BMI-SDS), and Liver Longitudinal Dimension (LLD) percentile. The BMI-SDS was the only independent predictor of NAFLD and LVMI.

Conclusions: LVH and NAFLD are two important and independent covariates in obese children. Obese children with or without hypertension have significant LVH as compared with non-obese control subjects. NAFLD and casual blood pressure measurements are not predictors of LVMI in obese children.

Keywords: Children; Obesity; Left ventricle mass index; Non-alcoholic fatty liver disease

Introduction

The prevalence of childhood obesity is increasing, not only in developed countries, but also in some developing countries [1]. It is associated with several risk factors for later heart disease and other chronic diseases, including hyperlipidemia, hyperinsulinemia, hypertension, and early atherosclerosis [2]. Children who are overweight and obese are more likely to become overweight and obese adults [3].

Non-Alcoholic Fatty Liver Disease (NAFLD) describes a spectrum of liver damage, ranging from simple steatosis to steatohepatitis, advanced fibrosis, and cirrhosis in persons who have not consumed alcohol so as to cause liver damage, and in whom no other etiology for fatty liver is present. An increased prevalence of NAFLD has been observed along with a dramatic rise in obesity in children during the past three decades. Obesity and insulin resistance are hallmarks of NAFLD. The exact prevalence of NAFLD is unclear. Pooling data from studies performed primarily in tertiary medical centers, the reported prevalence of NAFLD in obese children ranges from 20 to 77% [1,4-6].

Left Ventricular Hypertrophy (LVH) has prognostic importance in adults and is generally considered to have a similar prognostic value in children. Numerous population-based and hypertensive cohort studies investigating the impact of adiposity on left ventricle structure have shown that LVH is more prevalent in obese individuals than in their lean counterparts [7,8]. No reported study has analyzed the relationship between NAFLD and the Left Ventricle Mass Index (LVMI) in obese children. Thus, this study investigated the risk factors for left ventricle hypertrophy and determined the relationship between NAFLD and the LVMI in obese children.

Material and Methods

This was a cross-sectional study that included 98 obese children and 48 age- and gender-matched non-obese children as a control group. Subjects were enrolled randomly from among the obese children admitted to the Pediatric Endocrinology Department of Ankara Research and Training Hospital. To compare variables that differed significantly between the obese children and controls, the obese children were subdivided into two groups according to the presence of NAFLD.

*Corresponding author: Prof. Dr. Enver Simsek, Department of Pediatrics, Division of Pediatric Endocrinology, Eskisehir Osmangazi University, School of Medicine, Eskisehir, Turkey. Tel: +9050549623402; E-mail: enversimsek06@hotmail.com

Received February 24, 2012; Accepted May 26, 2012; Published May 25, 2012


Copyright: © 2012 Selver B. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Inclusion criteria included a Body Mass Index (BMI) ≥ 95th percentile for age and gender. Children were excluded if they had any condition known to influence body composition, insulin action, or insulin secretion (e.g., glucocorticoid therapy, hypothyroidism, Cushing's syndrome), or a history of medication use that could affect body mass or lipid profile. Children were also excluded if they had a history of medication use that causes liver inflammation, diabetes mellitus, or tested positive for hepatitis B or C.

At enrollment, the subjects all underwent physical examinations that included weight, standing height, BMI, and blood pressure measurements. Height was measured to the nearest 0.1 cm without shoes using a Harpenden stadiometer (Harpenden, Holtain, UK). Weight was measured to the nearest 0.1 kg on a standard beam scale with the subject dressed only in light underwear and without shoes. All measurements were repeated twice.

The weight status was recorded as the BMI, which was calculated as weight (kg)/height2 (m). Because the BMI changes rapidly with normal growth, and varies with age and gender, it was standardized for age and gender by converting to a “z score” [9]. Data were expressed as the Body Mass Index-Standard Deviation Score (BMI-SDS), which was calculated as [individual measurement-population mean]/population SD. Obesity was defined as a BMI ≥ 95th percentile according to reference curves for Turkish children [10]. The waist circumference was measured at the smallest point between the iliac crest and rib cage, and the hip circumference was measured at the largest width over the greater trochanter.

The resting Systolic (SBP) and Diastolic (DBP) Blood Pressures were measured twice in the right arm after a 10-min rest in a supine position by one investigator using a standard mercury sphygmomanometer and a validated protocol [11]. All subjects were considered hypertensive when the SBP or DBP was ≥ 95th percentile for age, gender, and height according to a percentiles chart for Turkish children [12]. Patients with evidence of secondary hypertension and those already on antihypertensive medication were excluded. Secondary hypertension was excluded by history, physical examination, serum chemistry, urinalysis, renal ultrasound, and other tests as indicated. Obese subjects were divided into four groups (with or without NAFLD and with or without hypertension) to compare the frequency of LVMI and LVH.

Biochemical analysis

After an overnight fast, blood samples were taken for the analysis of serum glucose, plasma insulin, Total Cholesterol (TC), Triglycerides (TG), Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Hepatitis B surface Antigen (HBsAg), and anti-Hepatitis C Virus antibody (anti-HCV). Glucose was measured using the glucose-oxidase colorimetric method using an automated analyzer (Hitachi, Roche Diagnostics, Mannheim, Germany). Fasting insulin was analyzed with a radio-immunochemical method (Pharmacia & Upjohn Diagnostics AB, Uppsala, Sweden). The detection limit was 0.5 µU/mL, and the intra- and interassay coefficients of variation were 6.5 and 9.1%, respectively. The homeostasis model assessment of insulin resistance (HOMA-IR) was used to evaluate insulin sensitivity [13]. The HOMA-IR was calculated as HOMA-IR = [fasting insulin (µU/mL) × fasting glucose (mmol/L)] / 22.5. A HOMA-IR > 3.16 was taken as a surrogate measure of insulin resistance [14].

The ALT, AST, fasting TC, and TG were measured using enzymatic colorimetric methods on an automated analyzer (Hitachi 904, Roche Diagnostics). Elevated liver enzymes were defined an ALT or AST ≥ 40 units/L. Cut-off points ≥ 95th percentile of healthy children were used to define dyslipidemia in accordance with international recommendations. These cut-off points were 200 mg/dl (5.1 mmol/L) for cholesterol and 150 mg/dl (1.7 mmol/L) for triglycerides [15]. HBsAg and anti-HCV were measured using microparticle enzyme immunoassays (Abbott Laboratories, Abbott Park, IL, USA).

Liver ultrasound and echocardiographic examination

An ultrasound examination was performed to identify NAFLD and to measure the Liver Longitudinal Dimension (LLD). The procedure was carried out by an experienced radiologist who was unaware of both the study aims and the participants’ biochemical profiles. An ultrasound device (GE LOGIQa 100 MP, GE Medical System, Milwaukie, WI, USA) with a 5-mHz probe in younger children and a 3.5-mHz probe in larger or markedly obese children was used. Fatty liver was diagnosed based on the ultrasonographic pattern and graded as absent, mild, moderate, and severe, according to the criteria of Needleman et al. [16]. In this study, the diagnosis of NAFLD was based on sonographic evidence of a fatty liver and negative test results for HBsAg and anti-HCV antibody. No participant had a history of liver disease, hypertension, or diabetes.

Echocardiograms were performed in all study subjects to evaluate LVH. All echocardiography was conducted by a single cardiologist. To determine the Left Ventricular Mass Index (LVM), two-dimensional echocardiography was performed in M-mode (General Electric Vivid 3, Norway) according to the guidelines of the American Society of Echocardiography [17]. All measurements were made at end-diastole, which was defined as the time of the maximum left ventricle dimension. Electronic calipers were used to measure the left ventricle internal diameter, interventricular septal thickness, and left ventricle posterior wall thickness from the M-mode images. The measurements were repeated over three consecutive cardiac cycles and averaged. The Devereux formula was used to estimate the LVM [18]. Because the LVM increases during growth and normal must be defined in the context of body size, the Left Ventricular Mass Index (LVM/L) was calculated for all children as LVM in grams divided by height in meters to the 2.7th power [19,20]. Using pediatric criteria, Left Ventricle Hypertrophy (LVH) was defined as LVMI ≥ 95th percentile for gender, which was 39.36 g/m2 for boys and 36.88 g/m2 for girls [21].

The study was conducted in accordance with the guidelines proposed in the Declaration of Helsinki and was approved by the Ethics Committee of Ankara Research and Training Hospital. Written informed consent was obtained from all participants over 12 years of age, and informed parental consent was obtained for all children regardless of age.

Statistical Analysis

Statistical analyses were performed using the Statistical Package for the Social Sciences (SPSS/PC+, ver. 13.0, Chicago, IL, USA). The following variables were included in the analysis: clinical data [Weight Standard Deviation Score (WSDS), Height Standard Deviation Score (HSDS)], BMI-SDS, SBP, DBP, and pubertal status [22]), biochemical parameters (fasting serum insulin and glucose concentrations, and HOMA-IR), LLD, NAFLD, LVM, and LVMI. The data are expressed as the mean ± standard deviation (SD) or median (min-max) where appropriate. Test selection was based on evaluating the variables for a normal distribution using the Shapiro–Wilk test. If the variables were distributed normally, a Student’s t-test was used; otherwise, the Mann-Whitney U-test was used. Categorical data were evaluated using Pearson’s chi-squared or Fisher’s exact test where applicable. Statistical correlations were calculated using Spearman’s correlation. Multiple linear regression analysis was performed with LVM and NAFLD as dependent variables, and age, BMI-SDS, HOMA-IR, AST, ALT, and LLD
Results

Of the participants, six were excluded because they tested positive for HBsAg (n = 5) or anti-HCV (n = 1). The study included 98 obese children and 48 non-obese control children. Of the obese subjects, 43 had NAFLD and 55 did not. The physical characteristics, laboratory results, LLD, LVM, and LVMI of the obese children and controls are summarized in Table 1. Compared with the controls, the obese children had significant differences in several clinical risk factors, including body weight, BMI, BMI-SDS, SBP, waist circumference, hip circumference, and waist/hip ratio (all p < 0.001). Nineteen (19.4%) of the 98 obese children had systolic or diastolic hypertension; none of the control subjects did. Insulin resistance was seen in 66 (67%) of the obese children and only two (4%) of the controls. The median LLD percentile in obese children and control subjects was the 82.5 (5–95) and 68.2) and 29.7 (15.6–42.0) g/m2.7, respectively (< 0.001). Forty-three (44%) of the 98 obese children had systolic or diastolic hypertension; none of the control subjects did. Insulin resistance was seen in 66 (67%) of the obese children and only two (4%) of the controls. The median LLD percentile in obese children and control subjects was the 82.5 (5–95) and 68.2) and 29.7 (15.6–42.0) g/m2.7, respectively (< 0.001).}

Table 1: Clinical characteristics, laboratory data, LLD percentile, LVM, and LVMI in obese children and non-obese controls.

<table>
<thead>
<tr>
<th></th>
<th>Obese children with NAFLD (N=43)</th>
<th>Obese children without NAFLD (N=55)</th>
<th>Control subjects (N=48)</th>
<th>p1</th>
<th>p2</th>
<th>p3</th>
</tr>
</thead>
<tbody>
<tr>
<td>BMI-SDS</td>
<td>2.55 (2.27-2.84)</td>
<td>2.66 (2.37-2.95)</td>
<td>0.41 (-0.42-1.01)</td>
<td>&lt; 0.001</td>
<td>&lt; 0.001</td>
<td>0.18</td>
</tr>
<tr>
<td>LLD percentile</td>
<td>90 (75-95)</td>
<td>75 (50-90)</td>
<td>50 (25-75)</td>
<td>&lt; 0.001</td>
<td>&lt; 0.001</td>
<td>0.65</td>
</tr>
<tr>
<td>Triglyceride (mg/dl)</td>
<td>125 (88-149)</td>
<td>123 (92-158)</td>
<td>82 (63-117)</td>
<td>&lt; 0.001</td>
<td>&lt; 0.001</td>
<td>0.46</td>
</tr>
<tr>
<td>Total cholesterol (mg/dl)</td>
<td>167 (± 29)</td>
<td>164 (± 27)</td>
<td>141 (± 25)</td>
<td>&lt; 0.001</td>
<td>&lt; 0.001</td>
<td>0.84</td>
</tr>
<tr>
<td>ALT (U/L)</td>
<td>19 (7-199)</td>
<td>17 (9-35)</td>
<td>1.9 (0.7-4.4)</td>
<td>&lt; 0.001</td>
<td>&lt; 0.001</td>
<td>0.742</td>
</tr>
<tr>
<td>AST (U/L)</td>
<td>23 (11-96)</td>
<td>24 (15-40)</td>
<td>82 (33-207)</td>
<td>&lt; 0.001</td>
<td>&lt; 0.001</td>
<td>0.005</td>
</tr>
<tr>
<td>NAFLD</td>
<td>43 (43.9%)</td>
<td>41 (2.1%)</td>
<td>118.9 (63.3-243.5)</td>
<td>&lt; 0.001</td>
<td>&lt; 0.001</td>
<td>0.005</td>
</tr>
<tr>
<td>LVMI (g/m2.7)</td>
<td>40.1 (26.4-98.2)</td>
<td>29.7 (15.6-42.0)</td>
<td>0.005</td>
<td>&lt; 0.001</td>
<td>&lt; 0.001</td>
<td>0.92</td>
</tr>
</tbody>
</table>

The data are expressed as the mean ± SD or median (25%-75%) where appropriate; BMI-SDS: Body Mass Index – Standard Deviation Score; LLD: Liver Longitudinal Dimension Percentile; ALT: Alanine Aminotransferase; NAFLD: Non-Alcoholic Fatty Liver Disease; LLM: Left Ventricle Mass; LVMI: Left Ventricle Mass Index.

*p1: obese children with NAFLD vs. control; p2: obese children without NAFLD vs. control; p3: obese children with NAFLD vs. obese without NAFLD

Table 2: Obesity related risk factors in obese children with NAFLD, obese children without NAFLD, and control subjects*.

<table>
<thead>
<tr>
<th></th>
<th>Obese children with NAFLD (N=43)</th>
<th>Obese children without NAFLD (N=55)</th>
<th>Control subjects (N=48)</th>
<th>p1</th>
<th>p2</th>
<th>p3</th>
</tr>
</thead>
<tbody>
<tr>
<td>BMI-SDS</td>
<td>2.55 (2.27-2.84)</td>
<td>2.66 (2.37-2.95)</td>
<td>0.41 (-0.42-1.01)</td>
<td>&lt; 0.001</td>
<td>&lt; 0.001</td>
<td>0.18</td>
</tr>
<tr>
<td>LLD percentile</td>
<td>90 (75-95)</td>
<td>75 (50-90)</td>
<td>50 (25-75)</td>
<td>&lt; 0.001</td>
<td>&lt; 0.001</td>
<td>0.65</td>
</tr>
<tr>
<td>Triglyceride (mg/dl)</td>
<td>125 (88-149)</td>
<td>123 (92-158)</td>
<td>82 (63-117)</td>
<td>&lt; 0.001</td>
<td>&lt; 0.001</td>
<td>0.46</td>
</tr>
<tr>
<td>Total cholesterol (mg/dl)</td>
<td>167 (± 29)</td>
<td>164 (± 27)</td>
<td>141 (± 25)</td>
<td>&lt; 0.001</td>
<td>&lt; 0.001</td>
<td>0.84</td>
</tr>
<tr>
<td>ALT (U/L)</td>
<td>19 (7-199)</td>
<td>17 (9-35)</td>
<td>1.9 (0.7-4.4)</td>
<td>&lt; 0.001</td>
<td>&lt; 0.001</td>
<td>0.742</td>
</tr>
<tr>
<td>AST (U/L)</td>
<td>23 (11-96)</td>
<td>24 (15-40)</td>
<td>82 (33-207)</td>
<td>&lt; 0.001</td>
<td>&lt; 0.001</td>
<td>0.005</td>
</tr>
<tr>
<td>NAFLD</td>
<td>43 (43.9%)</td>
<td>41 (2.1%)</td>
<td>118.9 (63.3-243.5)</td>
<td>&lt; 0.001</td>
<td>&lt; 0.001</td>
<td>0.005</td>
</tr>
<tr>
<td>LVMI (g/m2.7)</td>
<td>40.1 (26.4-98.2)</td>
<td>29.7 (15.6-42.0)</td>
<td>0.005</td>
<td>&lt; 0.001</td>
<td>&lt; 0.001</td>
<td>0.92</td>
</tr>
</tbody>
</table>

The data are expressed as the mean ± SD or median (25%-75%) where appropriate; BMI-SDS: Body Mass Index – Standard Deviation Score; LLD: Liver Longitudinal Dimension Percentile; ALT: Alanine Aminotransferase; NAFLD: Non-Alcoholic Fatty Liver Disease; LLM: Left Ventricle Mass; LVMI: Left Ventricle Mass Index.

*p1: obese children with NAFLD vs. control; p2: obese children without NAFLD vs. control; p3: obese children with NAFLD vs. obese without NAFLD

*Student’s t-test
*Pearson’s chi-squared test
*Mann Whitney U test
*Fisher’s exact test
and left ventricle mass (LVM) and LVMI index. 

Mass Alanine Aminotransferase; LLD: Liver Longitudinal Dimension; LVM: Left Ventricle Model Assessment of Insulin Resistance; AST: Aspartate Aminotransferase; ALT: BMI-SDS: Body Mass Index-Standart Deviation Scores; HOMA-IR: Homeostasis Model Assessment of Insulin Resistance; AST: Aspartate Aminotransferase; ALT: 

Table 3: Univariate Spearman’s correlation coefficients between the study variables and body mass index-standart deviation scores (BMI-SDS).

<table>
<thead>
<tr>
<th>Variable</th>
<th>Study Variable</th>
<th>BMI-SDS</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>Glucose</td>
<td>- 0.075</td>
<td>0.369</td>
<td></td>
</tr>
<tr>
<td>Insulin</td>
<td>0.470</td>
<td>&lt; 0.001</td>
<td></td>
</tr>
<tr>
<td>HOMA-IR</td>
<td>0.436</td>
<td>&lt; 0.001</td>
<td></td>
</tr>
<tr>
<td>Triglyceride</td>
<td>0.362</td>
<td>&lt; 0.001</td>
<td></td>
</tr>
<tr>
<td>Total cholesterol</td>
<td>0.446</td>
<td>&lt; 0.001</td>
<td></td>
</tr>
<tr>
<td>AST</td>
<td>0.033</td>
<td>0.694</td>
<td></td>
</tr>
<tr>
<td>ALT</td>
<td>0.270</td>
<td>&lt; 0.001</td>
<td></td>
</tr>
</tbody>
</table>

HOMA-IR: Homeostasis Model Assessment of Insulin Resistance; AST: Aspartate Aminotransferase; ALT: Alanine Aminotransferase

Table 4: Univariate Spearman’s correlation coefficients between the study variables and left ventricle mass (LVM) and LVMI index.

<table>
<thead>
<tr>
<th>Variable</th>
<th>Study Variable</th>
<th>LVM</th>
<th></th>
<th>LVMI</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td>0.526</td>
<td>&lt;0.001</td>
<td>0.094</td>
<td>0.259</td>
<td></td>
</tr>
<tr>
<td>BMI-SDS</td>
<td>0.561</td>
<td>&lt;0.001</td>
<td>0.675</td>
<td>&lt;0.001</td>
<td></td>
</tr>
<tr>
<td>HOMA-IR</td>
<td>0.490</td>
<td>&lt;0.001</td>
<td>0.250</td>
<td>0.002</td>
<td></td>
</tr>
<tr>
<td>AST</td>
<td>0.221</td>
<td>0.007</td>
<td>0.007</td>
<td>0.935</td>
<td></td>
</tr>
<tr>
<td>ALT</td>
<td>0.060</td>
<td>0.473</td>
<td>0.155</td>
<td>0.062</td>
<td></td>
</tr>
<tr>
<td>LLD percentile</td>
<td>0.540</td>
<td>&lt;0.001</td>
<td>0.331</td>
<td>&lt;0.001</td>
<td></td>
</tr>
</tbody>
</table>


Figure 1: Adjusted pair-wise comparison of the left ventricle mass index (LVMI) of obese children with non-alcoholic fatty liver disease (NAFLD), obese children without NAFLD, and control subjects.

In the univariate Spearman’s correlation analysis, BMI-SDS was directly related to the fasting insulin level, HOMA-IR, TG, TC, and ALT levels (Table 3), whereas, LVMI was positively correlated with BMI-SDS, HOMA-IR, and LLD percentile (Table 4). In the multiple linear regression analysis, LVMI (β = 0.119; p < 0.001) and NAFLD (β = 0.213; p < 0.001) remained independent correlates of BMI-SDS. The Spearman’s correlation analysis indicated no significant correlation between blood pressure and LVMI. In multiple linear regression models with NAFLD, BMI-SDS, SBP, and DBP as covariates, NAFLD was a significant predictor of LVMI (β = 3.4, p < 0.001). When BMI-SDS was added to the model, NAFLD as a predictor of LVMI was strongly attenuated and no longer statistically significant (β = 0.4). BMI-SDS remained a significant predictor of LVMI (β = 0.3, p < 0.001). When SBP and DBP were added to the model, the NAFLD association was also attenuated (β = 0.4). BMI-SDS remained a significant predictor of LVMI (β = 0.3, p < 0.001). SBP and DBP were not significant predictors of LVMI (β = 0.007) (Table 5).

Discussion

In addition to the current rise in obesity, NAFLD is becoming responsible for a large percentage of liver disease in children [1]. The actual prevalence of NAFLD remains unknown largely because of the lack of population-based studies and reliable noninvasive screening tools. The reported frequency of NAFLD is 20% of obese children and adolescents from the US [22], 44% from Italy [23], and 74% from China [24]. In the present study, the frequency of NAFLD was 44% in obese subjects.

NAFLD encompasses a spectrum of diseases, from asymptomatic steatohepatitis to cirrhosis. The pathogenesis of NAFLD has remained poorly understood since the earliest description of the disease. Studies have reported the pathophysiology of NAFLD in obese patients in detail [1,25,26]. Insulin resistance and oxidative stress have critical roles in NAFLD pathogenesis. The molecular basis of the association between insulin resistance and hepatic steatosis is unclear. In this study, fasting insulin level, HOMA-IR ALT (as a parameter of insulin resistance), TG, TC, and ALT did not differ between obese children with and without NAFLD. In multiple regression analyses, insulin resistance itself was not an independent predictor of NAFLD, whereas the severity of obesity (as BMI-SDS) showed a significant correlation with NAFLD. In contrast, some studies have reported that insulin resistance is associated with the development of NAFLD in obese subjects [27,28]. Taken together, previous results and our current findings suggest that the molecular pathogenesis of insulin resistance is multifactorial. Mildly to moderately elevated serum ALT or AST levels are the most common and often the only laboratory abnormalities in NAFLD. In previous studies, the frequency of an elevated ALT level was between 10...
and 30% in subjects with NAFLD [29,30]. In our study, the ALT levels differed significantly between obese children and controls, whereas no significant difference was observed between obese children with and without NAFLD. Only 8 of 43 (18.6%) obese children with NAFLD had abnormal ALT levels. A large portion of obese children may be missed at screening based only on serum aminotransferases. Fishbein et al. [31] reported that enzymatic abnormalities in fatty livers occur only in severe cases. Furthermore, Mofrad et al. [32] reported that the entire spectrum of NAFLD could be seen in subjects with normal ALT values. An ultrasound examination is preferred for identifying a fatty liver due to its noninvasiveness, availability, and high sensitivity and specificity. Joseph et al. [33] reported a sensitivity of 89% and specificity of 93% for detecting steatosis in the liver. Furthermore, we found that no subject with a normal liver ultrasound had an elevated ALT, and ultrasound revealed liver steatosis in all patients with elevated ALT levels. These findings suggest that an elevated ALT, higher BMI-SDS, and echogenic liver parenchyma, revealed by ultrasonography, are predictors of NAFLD.

The other obesity-related cardiovascular risk factors include an increased LVMI or LVH. A number of studies have examined the relationship between LVM, BP, and obesity (as BMI or BMI-SDS) with conflicting results. A high BP (i.e., BP > 95th percentile) of between 18 and 35% has been reported in overweight and obese children [34,35]. In this study, 19 of 98 (19.4%) obese children were hypertensive. The frequency of LVH differed significantly between the obese children and controls, whereas no significant difference was observed between the obese children with and without hypertension. In a multiple linear regression analysis of the obesity-related risk factors (BMI-SDS, glucose, fasting insulin levels, HOMA-IR, TC, and TGs) that may be responsible for the pathogenesis of increased LVMI, BMI-SDS was the only significant predictor of increased LVMI. Furthermore, in a multiple linear regression analysis, BP and NAFLD were not significant predictors of LVMI. Our findings are supported by previous studies [2,36-39]. The Bogalusa Heart Study showed a strong association between LVM in childhood and the degree of obesity, but childhood BMI was the only independent predictor for adult LVM [2]. Dhuper et al. [40] reported that obesity is a major predictor of concentric remodeling (CR) of the left ventricle, and the prevalence of CR of the left ventricle was similar in both the hypertensive and normotensive obese groups. Daniels et al. [41] showed a strong association between BMI and increased LVMI, independent of SBP. Finally, adult studies also reported that LVM is increased in normotensive obese adults, and that it is more closely associated with BMI and insulin resistance rather than BP [42,43]. Obesity affects cardiac muscle through multiple mechanisms. Factors other than BP, such as increased sympathetic activity, insulin resistance, vascular remodeling, neurohumoral modulation, volume overload, endothelial dysfunction, oxidative stress, and inflammation, which were not evaluated in the present study, may play a role in the pathogenesis of increasing LVMI in obese subjects. In contrast, some studies have shown that LVMI is positively associated with elevated BP [44-46]. Sorof et al. [47] found that LVMI is strongly correlated with 24-hour ambulatory measurements of the SBP index, whereas LVMI did not correlate with casual BP. Maggio et al. [48] reported a similar observation. In contrast, de Simone et al. [46] reported that the risk of LVH was significantly higher in children with a high casual BP as compared with children with normal BP, independent of the effects of obesity. These contradictory findings may be explained by different BP measurement methods and masked hypertension, which is defined as elevated ambulatory BP measurement without concomitant elevation of casual BP measurement.

Although NAFLD and increased LVMI or LVH are two important obesity-related covariates, this is the first study to identify a relationship between NAFLD and LVM in obese children. Components of Metabolic Syndrome (MS, i.e., hypertension, hyperinsulinism, dyslipidemia, impaired glucose tolerance, and obesity) are strongly associated with NAFLD [49,50]. Children with NAFLD often have multiple cardiovascular risk factors, including abnormal waist circumference, dyslipidemia, hypertension, insulin resistance [51], and increased carotid intima media thickness [52]. In a case control study comparing 150 pediatric patients with biopsy-proven NAFLD versus 150 overweight controls, children with MS had a five-fold increased risk of NAFLD [51]. Considering these studies, it can be concluded that NAFLD represents a liver manifestation of MS. It is well known that a major risk factor for mortality from MS is cardiovascular disease. Studies have shown that mortality among patients with NAFLD is higher than that in the general population, mainly due to concomitant cardiovascular diseases [53-56]. The natural history of NAFLD in the pediatric population is not clearly understood due to a lack of prospective studies evaluating children over time [57,58]. In our study, LVM was significantly higher in obese children with or without NAFLD as compared with non-obese children. However, LVMI was not significantly different between obese subjects with or without NAFLD. Furthermore, the multiple linear regression analysis revealed that NAFLD was not a significant predictor for LVMI and that BMI-SDS was the only main predictor of LVMI. The findings of this study highlight that there is no relationship between NAFLD and LVMI. This finding may be explained by the different pathophysiology of NAFLD and increased LVMI in obese children. The higher mortality rate secondary to cardiovascular diseases in NAFLD may be explained because NAFLD is a significant predictor of liver damage in MS.

Our study had two limitations. The current study was cross-sectional in design; therefore, temporal associations between obesity, BP elevation, LVMI, and NAFLD could not be evaluated. We used the method of casual BP measurement to screen for hypertension. Casual BP may not reflect the most comprehensive view of BP and may miss a diagnosis of hypertension.

In conclusion, this study has demonstrated that LVH and NAFLD are two important and independent obesity-related covariates in obese children. Obese children with or without hypertension have a higher frequency of LVH compared to non-obese control subjects. In addition, LVMI may be influenced by fat mass rather than casual BP. The 24-hour ambulatory BP measurement may be a potential tool to improve risk stratification in obesity studies. NAFLD and casual BP measurements are not predictors of LVMI in obese children. Collectively, NAFLD is an obesity-related risk factor for chronic liver disease and is expected to become one of the most common causes of end-stage liver disease in children.

References


